BOLD and Evonik led a €35m funding round in Abolis Biotechnologies.

BOLD, the corporate venture capital fund of L'Oréal, and Evonik, the corporate venture arm of Evonik Industries, led a €35m funding round in Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, with participation from DeepTech & Climate Fonds, Clay Capital, ICOS Capital, and Liberset. “We are delighted to announce the successful closing of our fundraise with leading industrial partners and industry-focused investors. This strategic funding will fuel our continued growth trajectory, strengthening our position as a European leader in biomanufacturing and microbiome solutions,” Cyrille Pauthenier, Abolis Biotechnologies CEO.